Return to Main Site 617-919-3019
401 Park Drive, 7th Floor East, Boston, MA 02215

TIDO Technology Search



Invention Type

Diagnostic/Prognostic
Information Technology/Software
Medical Device
Other
Research Tool
Therapeutics

Research Area

Allergy/Respiratory/Pulmonary Disease
Anesthesia
Audiology
Cardiovascular/Cardiology
Degenerative Disease
Dermatology
Endocrinology
Gastrointestinal/Nutrition
Genetic Disease
Health Care Management
Immunology
Infectious Disease
Inflammation
Internal Medicine
Metabolic Disease
Musculoskeletal
Neonatology/Pediatric
Neurology/Neuroscience
Oncology/Hematology
Ophthalmology
Orthopedics
Otolaryngology/Audiology
Pain
Pathology
Personalized Medicine
Psychiatric Disease
Radiology
Regenerative Medicine
Reproduction/Ob-Gyn
Stem Cell
Surgery/Wound Healing
Urology
CMCC 1993

Treating multiple myeloma with inhibitors of CXCR4

Inventors: Ulrich Von Andrian, Irina Mazo, Jean-Marc Gauguet

Invention Types: Therapeutics

Research Areas: Oncology/Hematology, Stem Cell

Keywords: Method of Use, Small Molecule/Drug

For More Information Contact:  Dietz, Ryan

 

Invention Description:

Researchers at the Immune Disease Institute have found that treating multiple myeloma may be possible with inhibitors of CXCR4, such as AMD3100 and anti-CXCR4 antibodies. The CXCR4 inhibitor disrupts or impedes the CXCR4 binding to the chemokine SDF-1a/CXCL12. The inhibitor is administered to the subject in need of such treatment as a pharmaceutical composition in amounts effective to interrupt the CXCR4-SDF pathway and to treat this disease. In experiments, a decreased expression of CXCR4 on multiple myeloma cells resulted in decreased homing of the cells to the bone marrow and a reduction in the development of the disease.


SDF-1a/CXCR4 signaling is active in the majority of cancer cells, including chronic lymphoid leukemia (CLL), chronic myeloid leukemia (CML), acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL), and non-Hodgkin's lymphoma (NHL). In addition, this signaling pathway is also active in solid tumors, such as rhabdomyosarcoma, prostate cancer and melanoma. Breast and lung cancers are known to metastasize to the bone marrow, using the SDF-1a/CXCR4 pathway in the process.

Applications:

• These treatment methods can be used independently, or in conjunction with, other therapies for the treatment of multiple myeloma.

• This treatment may also be used for chronic lymphoid leukemia (CLL), chronic myeloid leukemia (CML), acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL), and non-Hodgkin's lymphoma (NHL).

• The pharmaceutical composition is administered to a human subject over an extended period of time, for at least about 24 hours, and preferably at least about 6 days, and more preferably form about 6 days to about 40 days. The pharmaceutical composition typically includes a physiologically acceptable carrier and an adjuvant.

Competitive Advantages:

• The pharmaceutical composition can be used independently of other therapeutic compositions, or in combination with such other therapeutics.

• The pharmaceutical composition negatively affects homing and survival of multiple myeloma cells, originated somewhere else, in the bone marrow, the major targeted organ. Thus, the treatment targets the primary mechanism of multiple myeloma development.

Business Opportunity:

Outlicensing and research collaboration

Key Publications: US Patent 7,825,088; Published US 2011/0070244 A1

IPStatus: Patented